Shape memory paranasal sinus stent and preparation method thereof
By designing the shape memory sinus stent and its drug-loading membrane of the bionic octopus structure, the biocompatibility and fit of the existing sinus drug stent is solved, sequential administration and intelligent controlled release are achieved, reducing foreign body sensation and inflammation reaction.
Patent Information
- Application Number
- CN202411199317.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-06
AI Technical Summary
The main materials of existing degradable sinus drug stents have poor biocompatible properties, resulting in foreign body sensation and inflammatory reactions. The unreasonable structure is easily displaced or excreted, and cannot effectively fit the inner wall of the human sinus.
A shape memory sinus stent was designed, which consists of a stent body of a bionic octopus structure, a nanomedicine-loading fiber membrane and a hydrogel-loading fiber membrane. The stent body has a temporary shape and an initial shape, and is transformed by external stimulation. The degradation rates of the pharmaceutical fiber membrane and the hydrogel drug-loaded fiber membrane are different from each other to achieve sequential drug administration and intelligent controlled release.
It improves the fit between the stent and the human sinus, reduces foreign body sensation and inflammatory response, avoids displacement and discharge, realizes sequential administration and intelligent controlled release of drugs, and enhances the biocompatibility and safety of the stent.
Smart Images

Figure CN119074313A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of medical instruments and in particular to a shape memory sinus stent and a preparation method thereof. Background Art
[0002] Chronic rhinosinusitis (CRS) is a chronic inflammatory disease that occurs in the nasal cavity and sinus mucosa, with increased nasal secretions, nasal obstruction, headache and other symptoms as the main symptoms. Functional endoscopic sinus surgery is the preferred surgical treatment for CRS. It can remove irreversible lesions in the nasal cavity and sinuses of patients with chronic sinusitis and restore them to normal structural morphology. Due to problems such as postoperative management and compliance, there are adverse reactions such as adhesion, restenosis, scar formation, polyp recurrence and persistent inflammation, resulting in about 20% of CRS patients needing surgery again; the degradable sinus drug stent can be accurately implanted and support the sinus opening, and can continuously and quantitatively release hormone drugs, which can make up for the deficiencies after surgery to a certain extent.
[0003] In the related art, the main material of the degradable sinus drug stent product is generally made of polylactic acid copolymer, and most of the structure of the stent body is a hollow tubular diamond grid design. However, the main material of the above-mentioned stent product has poor biocompatibility with the human body, which causes patients to have a foreign body sensation and discomfort. In addition, the initial degradation product of the stent body is lactic acid, and the local acidic environment leads to an aggravated inflammatory response. In addition, since the structure of the human sinus is not regular, an unreasonable stent main structure is very likely to cause displacement or expulsion problems after implantation in the human body.
[0004] Therefore, based on the above problems, there is an urgent need to provide a shape memory sinus stent and a preparation method thereof. Summary of the invention
[0005] The embodiment of the present invention provides a shape memory sinus stent and a preparation method thereof. The shape memory sinus stent has good compatibility with the human body, and the structure of the stent body has good fit with the human nasal cavity structure and is not easily displaced or expelled.
[0006] In a first aspect, the present invention provides a shape memory sinus stent, comprising a stent body and a nano drug-loaded fiber membrane and a hydrogel drug-loaded fiber membrane sequentially coated on the surface of the stent body; wherein the stent body is composed of a top fixing point and a plurality of support bars uniformly arranged along the circumference of the top fixing point, one end of each support bar is connected to the top fixing point, and the other end is diffused in the direction away from the extension line of the top fixing point, so that the stent body has a bionic octopus structure;
[0007] The stent body includes a temporary shape and an initial shape, both of which are bionic octopus structures, the size of the stent body in the initial shape is larger than the size of the stent body in the temporary shape, and the shape memory sinus stent can be transformed from the temporary shape to the initial shape when subjected to external stimulation.
[0008] Preferably, each support bar is composed of a first arc close to the top fixed point and a second arc far from the top fixed point, the apex of the second arc is facing the extension line of the top fixed point, and the apex of the first arc is in the opposite direction to the apex of the second arc.
[0009] Preferably, the chord lengths of the first circular arcs in two adjacent support bars are different, and the chord lengths of the second circular arcs are also different.
[0010] Preferably, the support body further includes a plurality of top connecting members, wherein the top connecting members are located between two adjacent support bars and connected to the top fixing points.
[0011] Preferably, the support body further comprises a plurality of adsorbents, and the annular adsorbents are arranged on the support bar to enhance the adsorption between the support body and the nasal cavity.
[0012] More preferably, the adsorption component is composed of an annular adsorption disk and a cylindrical protrusion, and the cylindrical protrusion structure is located in the central area of the annular adsorption disk and is connected to the support bar.
[0013] Preferably, the degradation rates of the nano drug-loaded fiber membrane, the hydrogel drug-loaded fiber membrane and the stent body are different from each other.
[0014] More preferably, the degradation rates of the hydrogel drug-loaded fiber membrane, the nano drug-loaded fiber membrane and the stent body decrease in sequence.
[0015] Preferably, the raw materials for preparing the stent body include shape memory racemic polylactic acid, biomedical polymer materials, and plasticizers; wherein the biomedical polymer materials are polylactic acid, glycolic acid-lactic acid copolymer, polycaprolactone, polyethylene glycol, polysuccinic acid co-succinate, polyglycolic acid, polytrimethylene carbonate, poly-p-dioxanone or polyvinyl alcohol, and the plasticizer is a vegetable oil-based plasticizer, a plant-based plasticizer, a bio-based plasticizer or a citrate plasticizer.
[0016] More preferably, the raw material for preparing the stent body further includes a driving agent, and the driving agent is hollow copper sulfide particles.
[0017] Preferably, the raw materials for preparing the nano drug-loaded fiber membrane include shape memory racemic polylactic acid, biomedical polymer materials, additives and therapeutic drugs; wherein the additive is at least one of Centella asiatica, onion extract, chitosan, silk fibroin or chitosan, and the therapeutic drug is at least one of mometasone furoate, triamcinolone acetonide, budesonide, fluticasone propionate or beclomethasone propionate.
[0018] More preferably, the raw materials for preparing the hydrogel drug-loaded fiber membrane include natural polymer materials and therapeutic drugs; wherein the natural polymer material is at least one of chitosan, silk fibroin, sodium alginate, gelatin, hyaluronic acid, chitin or collagen.
[0019] In a second aspect, the present invention provides a method for preparing the shape memory sinus stent according to any one of the first aspects, the method comprising the following steps:
[0020] (1) constructing a three-dimensional structural model of the initial shape of the stent body according to the shape and size of the sinus structure;
[0021] (2) mixing shape memory racemic polylactic acid, biomedical polymer material and thermal driver to prepare shape memory polymer, using the shape memory polymer as printing line to perform 4D printing according to the three-dimensional structure model to obtain the stent body of the initial shape;
[0022] (3) preparing a nano drug-loaded fiber membrane and a hydrogel drug-loaded fiber membrane respectively by an electrospinning method, and coating the nano drug-loaded fiber membrane and the hydrogel drug-loaded fiber membrane on the surface of the stent body in sequence to obtain a shape memory sinus stent of an initial shape;
[0023] (4) The shape memory sinus stent of the initial shape is heated to above the glass transition temperature, a load is applied, and the shape memory sinus stent of the temporary shape is obtained after cooling and shaping.
[0024] Compared with the prior art, the present invention has at least the following beneficial effects:
[0025] In the present invention, firstly, the structure of the stent body is designed as a bionic octopus structure, and the size parameters of the stent body structure are adjusted according to the human sinus structure, so that it can fit well with the inner wall of the human sinus, thereby effectively avoiding the problem of displacement or discharge of the stent body; then, by sequentially arranging nano drug-loaded fiber membranes and hydrogel drug-loaded fiber membranes for carrying different therapeutic effects on the surface of the stent body, sequential drug administration and intelligent controlled release of drugs can be achieved, and the structure can be administered at the first time after surgery; when in use, the hydrogel drug-loaded fiber membrane first contacts the inner wall of the human sinus, thereby greatly reducing the discomfort and foreign body sensation of the human body, and at the same time, due to its certain adhesion, it can also effectively avoid the problem of displacement or discharge of the stent body; further, the stent body has shape memory performance, when the stent is in a temporary shape, the size is small and easy to implant, when subjected to external stimulation, the stent body can be transformed from the temporary shape to the larger initial shape, and in the process of shape memory recovery, due to the influence of the resistance of the inner wall of the sinus, the shape memory sinus stent can be completely fitted with the inner wall of the sinus, reducing the patient's foreign body sensation. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0027] Figure 1 It is a schematic diagram of the overall structure of a shape memory sinus stent provided by one embodiment of the present invention;
[0028] Figure 2 It is a schematic diagram of the initial shape structure of a stent body in a shape memory sinus stent provided by one embodiment of the present invention;
[0029] Figure 3 is a schematic diagram of the initial shape structure of a stent body in a shape memory sinus stent provided by another embodiment of the present invention;
[0030] Figure 4 It is a schematic diagram of a temporary shape structure of a stent body in a shape memory sinus stent provided by one embodiment of the present invention;
[0031] Figure 5 It is a schematic diagram of the initial shape structure of a stent body in a shape memory sinus stent provided by another embodiment of the present invention;
[0032] Figure 6 It is a schematic diagram of a temporary shape structure of a stent body in a shape memory sinus stent provided by one embodiment of the present invention;
[0033] In the figure, 100-stent body, 200-nano drug-loaded fiber membrane, 300-hydrogel drug-loaded fiber membrane, 101-top fixing point, 102-support bar, 1021-first arc, 1022-second arc, 103-top connecting piece, 104-adsorption piece, 1041-annular adsorption disk, 1042-columnar protrusion. DETAILED DESCRIPTION
[0034] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0035] like Figures 1 to 4 As shown, the present invention provides a shape memory sinus stent, comprising a stent body 100 and a nano drug-loaded fiber membrane 200 and a hydrogel drug-loaded fiber membrane 300 sequentially coated on the surface of the stent body 100; wherein the stent body 100 is composed of a top fixing point 101 and a plurality of support bars 102 uniformly arranged along the circumference of the top fixing point 101, one end of each support bar 102 is connected to the top fixing point 101, and the other end is diffused in the direction away from the extension line of the top fixing point 101, so that the stent body 100 presents a bionic octopus structure;
[0036] The stent body 100 includes a temporary shape and an initial shape, both of which are bionic octopus structures. The size of the stent body 100 in the initial shape is larger than the size of the stent body 100 in the temporary shape. The shape memory sinus stent can be transformed from the temporary shape to the initial shape when subjected to external stimulation.
[0037] In the embodiment of the present invention, firstly, the structure of the stent body 100 is designed as a bionic octopus structure, and the size parameters of the structure of the stent body 100 are adjusted according to the human sinus structure, so that it can fit well with the inner wall of the human sinus, thereby effectively avoiding the problem of displacement or discharge of the stent body 100; then, by sequentially arranging the electrospun nano drug-loaded fiber membrane 200 and the hydrogel drug-loaded fiber membrane 300 for carrying different therapeutic drugs on the surface of the stent body 100, the electrospun nano drug-loaded fiber membrane 200 has a large specific surface area and a unique mesh structure, so that the controlled release function of the drug can be achieved, and the hydrogel drug-loaded fiber membrane 300 has a high water content, high elasticity and high specific surface area. When used, the hydrogel drug-loaded fiber membrane 300 first contacts the inner wall of the human sinus, thereby greatly reducing the discomfort and foreign body sensation of the human body. At the same time, due to a certain degree of adhesion, the problem of displacement or discharge of the stent body can also be effectively avoided. In addition, through the design of the above structure, the drug can be administered at the first time after surgery, and sequential administration and intelligent controlled release of drugs can be achieved.
[0038] Furthermore, the stent body 100 has shape memory properties. When the stent is in a temporary shape, it is small in size and easy to implant. When subjected to external stimuli, the stent body 100 can be transformed from the temporary shape to an initial shape with a larger size. During the shape memory recovery process, due to the resistance of the inner wall of the sinus, the shape memory sinus stent can fit completely with the inner wall of the sinus, reducing the patient's foreign body sensation.
[0039] like Figure 2 As shown, according to some preferred embodiments, each support bar 102 is composed of a first arc 1021 close to the top fixed point 101 and a second arc 1022 away from the top fixed point 101, the apex of the second arc 1022 is toward the extension line of the top fixed point 101, and the direction of the apex of the first arc 1021 is opposite to the direction of the apex of the second arc 1022.
[0040] Depend on Figure 2 It can be seen that in the embodiment of the present invention, the structure of each support bar 102 is further arranged so that the support bar 102 is composed of two interconnected arcs, and the arc tops of the two arcs are set to be in opposite directions. This is not only beneficial for the stent body to better support the sinuses, maintain the patency of the sinuses, prevent sinus adhesions, keep the sinus opening open, continuously inhibit inflammatory response and reduce postoperative adhesions, but also helps to ensure that the stent body has a good fit with the inner wall of the human sinus.
[0041] According to some preferred embodiments, the chord lengths of the first arcs 1021 in two adjacent support bars 102 are different, and the chord lengths of the second arcs 1022 are also different.
[0042] In the embodiment of the present invention, continue to refer to Figure 2 or Figure 3 , the chord lengths corresponding to the two arcs in two adjacent support bars 102 are different, and, further, in two adjacent support bars 1023 and 1024, the chord length corresponding to the first arc 1021 in the support bar 1023 close to the top fixed point 101 is smaller than the chord length corresponding to the first arc 1021 in the support bar 1024 close to the top fixed point 101, and the chord length corresponding to the first arc 1021 in the support bar 1023 away from the top fixed point 101 is greater than the chord length corresponding to the first arc 1021 in the support bar 1024 away from the top fixed point 101, which is beneficial to further enhance the fit between the stent body 100 and the inner wall of the human sinus.
[0043] It should be noted that when the number of the support bars 102 in the stent body 100 is 6-12, the stent body 100 can have excellent supporting performance while having a good fit with the inner wall of the human sinus.
[0044] like Figure 5 As shown, according to some preferred embodiments, the support body 100 further includes a plurality of top connecting members 103 , and the top connecting member 103 is located between two adjacent support bars 102 and connected to the top fixing point 101 .
[0045] In an embodiment of the present invention, a top connecting piece 103 is further provided on the bracket body 100, the number of the top connecting pieces 103 is less than the number of the support bars 102, and the top connecting pieces 103 are located at one end of the first arc 1021 of two adjacent support bars 102, and are connected to the top fixing point 101. In this way, the upper end of the bracket body 100 can be designed in an umbrella shape, thereby enhancing the mechanical properties of the top end of the bracket body 100 and preventing the support bars 102 from breaking.
[0046] At the same time, in order to make the stent body 100 conform to the size of the human sinus and provide better support for the inner wall of the sinus, and at the same time enable the drugs in the two layers of drug-loaded fiber membrane on the surface of the stent body 100 to be evenly released to the inner wall of the sinus after being implanted in the inner wall of the human sinus, the maximum diameter of the umbrella-shaped structure formed by the top connecting piece 103 in the embodiment of the present invention connecting each support bar 102 is 10 mm.
[0047] Continue to refer Figure 5According to some preferred embodiments, the bracket body also includes a plurality of adsorption components 104, which are arranged on the support bar 102 to enhance the adsorption of the bracket body and the nasal cavity; the adsorption component 104 is composed of an annular adsorption disk 1041 and a cylindrical protrusion 1042, and the cylindrical protrusion 1042 structure is located in the central area of the annular adsorption disk 1041 and is connected to the support bar 102.
[0048] In the embodiment of the present invention, further, by providing an adsorbent 104 composed of an annular adsorption disk 1041 and a columnar protrusion located in the central area of the annular adsorption disk 1041 on the support bar 102, not only can the stent body 100 be better fixedly connected with the nano drug-loaded fiber membrane 200 and the hydrogel drug-loaded fiber membrane 300, but also after the two layers of drug-loaded fiber membrane on the surface of the stent body 100 are degraded, the stent body 100 and the inner wall of the sinus still have good adsorption, so that the stent body 100 can better support the inner wall of the sinus to prevent it from falling off. In the embodiment of the present invention, the adsorbent 104 is provided in the middle area of at least four support bars 102 to achieve a good adsorption effect. At the same time, in order to avoid the human body from having a foreign body sensation, the annular adsorption disk 1041 and the columnar protrusion 1042 are 0.4mm-0.8mm higher than the surface of the support bar 102.
[0049] According to some preferred embodiments, the degradation rates of the nano drug-loaded fiber membrane, the hydrogel drug-loaded fiber membrane and the stent body are different; the degradation rates of the hydrogel drug-loaded fiber membrane, the nano drug-loaded fiber membrane and the stent body decrease in sequence and are degraded successively in the body.
[0050] Further considering that the whole surgical wound healing process will go through three different periods, in the embodiment of the present invention, by designing the arrangement order of the stent body, the hydrogel drug-loaded fiber membrane and the nano drug-loaded fiber membrane and the degradation rate of each layer, the hydrogel drug-loaded fiber membrane and the nano drug-loaded fiber membrane in the sinus stent can respectively achieve sequential drug administration and intelligent controlled drug release at different periods. Specifically, in the first period after the sinus stent is implanted, the soft hydrogel drug-loaded fiber membrane in the outermost layer can achieve accurate and low-dose effective drug administration in the first time after surgery to reduce the occurrence of postoperative inflammation, and can be degraded as early as one month; in the second period after the sinus stent is implanted, the drug-loaded nano fiber membrane in the middle layer can further release drugs to treat the scar hyperplasia period, and then degrade within two months; finally, after the two layers of drug-loaded fiber membrane on the surface of the stent body are degraded, the stent body can still support the inner wall of the sinus to keep the nasal cavity patency, prevent nasal adhesion, keep the sinus opening open, continuously inhibit inflammatory response, reduce postoperative adhesion and intervention, and finally degrade within three months.
[0051] In summary, through the design of each layer in the sinus stent and the control of the degradation rate, the sinus stent can fully play its role in all periods, and the sinus stent will gradually degrade in the human body. The sinus stent will not remain in the sinus for a long time, reducing or eliminating the risk of potential complications. It is safer for the human body and avoids secondary surgery to remove the stent, which can effectively relieve pain and bring a better experience.
[0052] According to some preferred embodiments, the raw materials for preparing the stent body include shape memory racemic polylactic acid, biomedical polymer materials, and plasticizers; wherein the biomedical polymer materials are polylactic acid, glycolic acid-lactic acid copolymer, polycaprolactone, polyethylene glycol, polysuccinic acid co-succinate, polyglycolic acid, polytrimethylene carbonate, poly-p-dioxanone or polyvinyl alcohol, and the plasticizer is a vegetable oil-based plasticizer, a plant-based plasticizer, a bio-based plasticizer or a citrate plasticizer; the raw materials for preparing the stent body also include a driver, and the driver is hollow copper sulfide particles.
[0053] In the embodiment of the present invention, the main material of the stent body is selected to be a mixture of medical-grade shape memory racemic polylactic acid and biomedical polymer materials, which not only makes the stent body have better shape memory performance and better compatibility with the human body, but also can reduce the occurrence of inflammatory response, thereby reducing the foreign body sensation and discomfort caused by the stent body implanted in the human body. Considering that the glass transition temperature of shape memory racemic polylactic acid is high when the shape memory sinus stent is driven by light or heat, in the embodiment of the present invention, a safe, non-toxic and degradable material is selected as a plasticizer, and it is mixed with shape memory racemic polylactic acid and biomedical polymer materials, so that the glass transition temperature of the stent body is reduced to 40-42°C, thereby reducing the discomfort caused to the human body when the sinus stent is stimulated. At the same time, in order to make the stent body have a light-responsive shape memory effect when light is driven, hollow copper sulfide nanoparticles with high light-to-heat conversion efficiency are added to the preparation material of the stent body; the light source for driving the shape memory sinus stent can be selected from near-infrared light.
[0054] It should be noted that in the embodiment of the present invention, the sinus stent can be transformed by different external stimulation methods. The different driving methods include but are not limited to one or more of thermal drive, electric drive, magnetic drive, light drive, sound drive, solution drive, pH drive, etc. Considering the comfort to the human body, thermal drive or light drive is preferably selected as the driving method of the sinus stent.
[0055] According to some preferred embodiments, in the stent body, the content of shape memory racemic polylactic acid is 70-90% (for example, it can be 70%, 80% or 90%), the content of biomedical polymer material is 10-30% (for example, it can be 10%, 20% or 30%), and the content of plasticizer is 5-20% (for example, it can be 5%, 10%, 15% or 20%); in the stent body, the added amount of the driving agent is 0.2-0.5g (for example, it can be 0.2g, 0.3g, 0.4g or 0.5g).
[0056] In the embodiment of the present invention, the stent body is prepared by mixing shape memory racemic polylactic acid, biomedical polymer materials and plasticizers of appropriate types and contents, which is conducive to preparing a stent body with good shape memory performance, biocompatibility and appropriate degradation rate.
[0057] According to some preferred embodiments, the raw materials for preparing the nano drug-loaded fiber membrane include shape memory racemic polylactic acid, biomedical polymer materials, additives and therapeutic drugs; wherein the additive is at least one of Centella asiatica, onion extract, chitosan, silk fibroin or chitosan, and the therapeutic drug is at least one of mometasone furoate, triamcinolone acetonide, budesonide, fluticasone propionate or beclomethasone propionate.
[0058] In the embodiments of the present invention, further combined with the period of postoperative wound healing, by adding specific types of additives and therapeutic drugs to the nano-drug-loaded fiber membrane, the above-mentioned types of additives can make the sinus stent have excellent effects such as promoting wound healing, anti-inflammation, anti-scarring, inhibiting fibroblast proliferation, promoting wound healing and promoting epithelialization. During the postoperative recovery process, the nano-drug-loaded fiber membrane can controllably release therapeutic drugs to achieve the treatment of sinusitis.
[0059] It should be noted that in the embodiments of the present invention, additives and therapeutic drugs include but are not limited to the above-mentioned types, and the types can also be selected according to the actual treatment effects.
[0060] According to some preferred embodiments, in the nano-drug loaded fiber membrane, the content of shape memory racemic polylactic acid is 80-95% (for example, it can be 80%, 90% or 95%), the content of biomedical polymer material is 5-20% (for example, it can be 5%, 15% or 20%), the content of additives is 5-10% (for example, it can be 5%, 8% or 10%), and the content of therapeutic drugs in the nano-drug loaded fiber membrane is 350-450μg (for example, it can be 350μg, 400μg or 500μg).
[0061] In the embodiment of the present invention, the nano drug-loaded fiber membrane is prepared by mixing shape memory racemic polylactic acid, biomedical polymer materials, additives and therapeutic drugs of appropriate types and contents and utilizing electrospinning method. This is not only beneficial for preparing the nano drug-loaded fiber membrane with good biocompatibility, but also beneficial for achieving controllable release of drugs from the nano drug-loaded fiber membrane within an appropriate degradation time, thereby treating the scar hyperplasia stage and achieving anti-scar and anti-inflammatory effects.
[0062] According to some preferred embodiments, the raw materials for preparing the hydrogel drug-loaded fiber membrane include natural polymer materials and therapeutic drugs; wherein the natural polymer material is at least one of chitosan, silk fibroin, sodium alginate, gelatin, hyaluronic acid, chitin or collagen.
[0063] In the embodiment of the present invention, since the postoperative wound healing process will first experience an inflammatory period, the hydrogel drug-loaded fiber membrane will first contact the inner wall of the sinus. Since the hydrogel drug-loaded fiber membrane is relatively soft, it can greatly reduce the discomfort and foreign body sensation of the patient after surgery. By adding natural polymer materials in the preparation process of the hydrogel drug-loaded fiber membrane, not only can the sinus stent have excellent effects such as hemostasis, accelerated human wound healing, reduced postoperative inflammation, and prevention of postoperative adhesion, but also the sinus stent can be given better adhesion, thereby further avoiding the problem of displacement or expulsion of the sinus stent.
[0064] According to some preferred embodiments, the content of natural polymer materials in the hydrogel drug-loaded fiber membrane is 80-100% (for example, it can be 80%, 90% or 100%), and the content of therapeutic drugs in the hydrogel drug-loaded fiber membrane is 200-300 μg (for example, it can be 200 μg, 250 μg or 300 μg).
[0065] In the embodiment of the present invention, the hydrogel drug-loaded fiber membrane is prepared by mixing the natural polymer material of appropriate type and content with the therapeutic drug, which is not only conducive to preparing the hydrogel drug-loaded fiber membrane with good biocompatibility and adhesion performance, but also conducive to achieving the controllable release of the drug in the hydrogel drug-loaded fiber membrane within a suitable degradation time, thereby treating the inflammatory period, having the effects of hemostasis, accelerating the healing of human wounds, reducing the occurrence of postoperative inflammation, and preventing postoperative adhesion.
[0066] At the same time, it should be noted that in the embodiments of the present invention, a certain amount of additives can be added in the preparation of the hydrogel drug-loaded fiber membrane according to actual treatment needs. The additive can be at least one of Centella asiatica, onion extract, chitosan, silk fibroin or chitosan, and the content of the additive can be 5-20%.
[0067] The embodiment of the present invention further provides a method for preparing the shape memory sinus stent as described in any one of the above items, the preparation method comprising the following steps:
[0068] (1) constructing a three-dimensional structural model of the initial shape of the stent body according to the specific structural shape and size of the patient's sinus;
[0069] (2) mixing shape memory racemic polylactic acid with a biomedical polymer material to prepare a shape memory polymer, and performing 4D printing according to the three-dimensional structure model using the shape memory polymer as a printing line to obtain a stent body of an initial shape;
[0070] (3) preparing a nano drug-loaded fiber membrane and a hydrogel drug-loaded fiber membrane respectively by an electrospinning method, and coating the nano drug-loaded fiber membrane and the hydrogel drug-loaded fiber membrane on the surface of the stent body in sequence to obtain a shape memory sinus stent of an initial shape;
[0071] (4) The shape memory sinus stent of the initial shape is heated to above the glass transition temperature, a load is applied, and the shape memory sinus stent of the temporary shape is obtained after cooling and shaping.
[0072] In the embodiment of the present invention, during use, the shape memory sinus stent is implanted into the nasal cavity, and the shape memory nasal stent (such as Figure 3 or 5) applying temperature, electromagnetic or light stimulation, and transforming the larger initial shape of the sinus stent into a smaller temporary shape of the sinus stent (such as Figure 4 or 6); then implant the temporary-shaped sinus stent into the sinus, apply external stimulation to the temporary-shaped sinus stent, so that the temporary-shaped sinus stent is transformed into the initial-shaped sinus stent until it fits to the human nasal mucosa.
[0073] According to some preferred embodiments, the preparation method of the drug-loaded nanofiber membrane is as follows: shape memory racemic polylactic acid and biomedical polymer materials are added to an organic solvent and stirred to obtain a mixed solution; additives and therapeutic drugs are sequentially added to the mixed solution, and the mixture is stirred to obtain a spinning solution; the spinning solution is injected into a syringe, and the drug-loaded nanofiber membrane is prepared by an electrospinning method; the organic solvent is dichloromethane;
[0074] The preparation method of the hydrogel drug-loaded fiber membrane is as follows: adding a natural polymer material to an organic solvent and stirring and mixing to obtain a mixed solution; adding a therapeutic drug to the mixed solution and stirring and mixing to obtain a spinning solution; injecting the spinning solution into a syringe and preparing a natural hydrogel by an electrospinning method;
[0075] Adding a synthetic polymer material (freeze-dried gelatin-hydroxyphenylpropionic acid) into an organic solvent and stirring and mixing to obtain a mixed solution; adding a therapeutic drug into the mixed solution and stirring and mixing to obtain a spinning solution; injecting the spinning solution into a syringe and preparing a synthetic hydrogel by an electrospinning method;
[0076] The natural hydrogel and the synthetic hydrogel are mixed and cross-linked at room temperature to obtain the hydrogel drug-loaded fiber membrane.
[0077] In the embodiment of the present invention, the nano drug-loaded fiber membrane and the hydrogel drug-loaded fiber membrane can be made by the electrospinning process in the prior art, and at the same time, the parameters in the 4D printing process can be adjusted according to the actual application. However, it should be noted that when preparing the hydrogel drug-loaded fiber membrane by electrospinning, mixing the synthetic hydrogel fiber with the natural hydrogel fiber can promote the cross-linking reaction of the relevant chemical groups in the fiber, so that the problem of poor mechanical properties of the hydrogel drug-loaded fiber membrane caused by adding natural polymer materials to the preparation materials of the hydrogel drug-loaded fiber membrane can be effectively avoided.
[0078] It should be noted that the freeze-dried gelatin-hydroxyphenylpropionic acid in the examples of the present invention can be purchased.
[0079] At the same time, taking into account the different treatment periods and different drug loading amounts, the thickness of the hydrogel drug-loaded fiber membrane in the embodiment of the present invention is less than the thickness of the nano drug-loaded fiber membrane. More specifically, the thickness of the hydrogel drug-loaded fiber membrane is 0.2-0.3mm, and the thickness of the nano drug-loaded fiber membrane is 0.4-0.5mm.
[0080] In order to more clearly illustrate the technical solution and advantages of the present invention, a shape memory sinus stent and a preparation method thereof are described in detail through several embodiments below.
[0081] Embodiment 1:
[0082] (1) Using the modeling software Solidworks to construct a three-dimensional structural model of the initial shape of the stent body according to the shape and size of the sinus structure, and using the Cura software to slice the model to obtain a 3D printed structural model that can be printed;
[0083] (2) 85 g of shape memory racemic polylactic acid, 5 g of plasticizer (tributyl citrate), and 10 g of biomedical polymer material (polycaprolactone) were added to an extruder and mixed to obtain a shape memory polymer, the extruder was preheated to 160° C., the traction machine speed was adjusted, and an extrusion line with a wire diameter of 1.75 mm was drawn out, and the collected extrusion line was installed on a 3D printer, and the constructed 3D printing structure model file was imported into the 3D printer, and the FDM printer was used for printing, and the printing parameters (temperature 190° C., speed 50%, fan speed 100%) were set to obtain a 4D printed initial shape of the bracket body;
[0084] (3) Preparation of drug-loaded nanofiber membrane: 8 g of shape memory racemic polylactic acid, 1.5 g of biomedical polymer material (polycaprolactone) and 0.5 g of additive (Centella asiatica) were added to an organic solvent (dichloromethane) and stirred for 12 h to prepare a mixed solution with a concentration of 13 wt%; 400 μg of therapeutic drug (mometasone furoate) was added to 100 mL of organic solvent (dichloromethane) and stirred to obtain a drug solution; the drug solution and the mixed solution were stirred for 4 h to obtain a uniformly mixed drug-loaded spinning solution. 10 mL of the drug-loaded spinning solution was poured into a syringe, the power supply was turned on, the voltage was set to 14 kV, the propulsion speed was 3 mL / h, the receiving distance was 20 cm, the temperature was room temperature 25°C, and the humidity was 20% to obtain a drug-loaded nanofiber membrane.
[0085] Preparation of hydrogel drug-loaded fiber membrane:
[0086] 1.5 g of synthetic polymer material (lyophilized gelatin-hydroxyphenylpropionic acid) was dissolved in a mixed solvent of 10 mL of hexafluoroisopropanol and ultrapure water (9:1) to obtain a mixed solution; 250 μg of therapeutic drug (mometasone furoate) was added to the mixed solution, and the electrospinning solution was obtained after mixing; the electrospinning solution was placed in a 10 mL syringe installed on a microinjection pump, the voltage was set to 18 kV, the rate was 3 mL / h, and a drum collector (diameter 10 cm, width 20 cm, rotation speed 1000 n / min) was placed 18 cm away from the injector nozzle to collect random microfibers to obtain a synthetic hydrogel;
[0087] 1.5 g of natural polymer material (lyophilized gelatin) was dissolved in a mixed solvent of 10 mL of hexafluoroisopropanol and ultrapure water (9:1) to obtain a mixed solution; 250 μg of therapeutic drug (mometasone furoate) was added to the mixed solution and mixed to obtain an electrospinning solution; the electrospinning solution was placed in a 10 mL syringe installed on a microinjection pump, the voltage was set to 18 kV, the rate was 3 mL / h, and a drum collector (diameter 10 cm, width 20 cm, rotation speed 1000 n / min) was placed 18 cm away from the injector nozzle to collect random microfibers to obtain a natural hydrogel; the synthetic hydrogel and the natural hydrogel were mixed and cross-linked at room temperature for 3 h to obtain a hydrogel drug-loaded fiber membrane.
[0088] The nano drug-loaded fiber membrane and the hydrogel drug-loaded fiber membrane are sequentially coated on the surface of the stent body to obtain a shape memory sinus stent of the initial shape;
[0089] (4) Raise the temperature to heat the initial shape of the shape memory sinus stent to above the glass transition temperature Tg. When the surface temperature of the sinus stent is higher than Tg, the stent body will soften. At this time, apply a load to the softened sinus stent to make the sinus stent shrink to the middle into a temporary shape. Leave the heat source and wait for the surface temperature of the sinus stent to drop below Tg. After standing for a few minutes and removing the load, the shape of the sinus stent can be fixed, thereby obtaining a temporary shape memory sinus stent.
[0090] Embodiment 2:
[0091] (1) Using the modeling software Solidworks to construct a three-structure model of the initial shape of the stent body according to the shape and size of the sinus structure, and using Cura software to slice the model to obtain a 3D printed structure model that can be printed;
[0092] (2) 85 g of shape memory racemic polylactic acid, 10 g of biomedical polymer material (polycaprolactone), 5 g of plasticizer (tributyl citrate) and 0.2 g of driver (hollow copper sulfide nanoparticles) were added to an extruder and mixed to obtain a shape memory polymer, the extruder was preheated to 160° C., the traction machine speed was adjusted, and an extrusion line with a wire diameter of 1.75 mm was drawn out, and the collected extrusion line was installed on a 3D printer, and the constructed 3D printing structure model file was imported into the 3D printer, and the FDM printer was used for printing, and the printing parameters (temperature 190° C., speed 50%, fan speed 100%) were set to obtain a 4D printed initial shape of the bracket body;
[0093] (3) Preparation of drug-loaded nanofiber membrane: 8 g of shape memory racemic polylactic acid, 1.5 g of biomedical polymer material (polycaprolactone) and 0.5 g of additive (Centella asiatica) were added to an organic solvent (dichloromethane) and stirred for 3 h to prepare a mixed solution with a concentration of 13 wt%; 500 μg of therapeutic drug (mometasone furoate) was added to 100 mL of organic solvent (dichloromethane) and stirred to obtain a drug solution; the drug solution and the mixed solution were stirred for 4 h to obtain a uniformly mixed drug-loaded spinning solution. 10 mL of the drug-loaded spinning solution was poured into a syringe, the power supply was turned on, the voltage was set to 14 kV, the propulsion speed was 3 mL / h, the receiving distance was 20 cm, the temperature was room temperature 25°C, and the humidity was 20% to obtain a drug-loaded nanofiber membrane.
[0094] Preparation of hydrogel drug-loaded fiber membrane:
[0095] 1.5 g of synthetic polymer material (lyophilized gelatin-hydroxyphenylpropionic acid) was dissolved in 10 mL of a mixed solvent of hexafluoroisopropanol and ultrapure water (9:1) to obtain a mixed solution; the electrospinning solution was placed in a 10 mL syringe mounted on a microinjection pump, the voltage was set to 18 kV, the rate was 3 mL / h, and a drum collector (10 cm in diameter, 20 cm in width, and a rotation speed of 1000 n / min) was placed 18 cm away from the injector nozzle to collect random microfibers to obtain a synthetic hydrogel;
[0096] 1.5 g of natural polymer material (lyophilized gelatin) was dissolved in a mixed solvent of 10 mL of hexafluoroisopropanol and ultrapure water (9:1) to obtain a mixed solution; 250 μg of therapeutic drug (mometasone furoate) was added to the mixed solution, and the electrospinning solution was obtained after mixing; the electrospinning solution was placed in a 10 mL syringe installed on a microinjection pump, the voltage was set to 18 kV, the rate was 3 mL / h, and a drum collector (diameter 10 cm, width 20 cm, rotation speed 1000 n / min) was placed 18 cm away from the injector nozzle to collect random microfibers to obtain a natural hydrogel; the synthetic hydrogel and the natural hydrogel were mixed and cross-linked at room temperature for 3 h to obtain a hydrogel drug-loaded fiber membrane;
[0097] The nano drug-loaded fiber membrane and the hydrogel drug-loaded fiber membrane are sequentially coated on the surface of the stent body to obtain a shape memory sinus stent of the initial shape;
[0098] (4) The shape memory sinus stent of the initial shape is heated to above the glass transition temperature Tg by near-infrared light irradiation. When the surface temperature of the sinus stent is higher than Tg, the stent body will soften. At this time, a load is applied to the softened sinus stent to make the sinus stent shrink to the middle into a temporary shape. The light source is removed and the surface temperature of the sinus stent is lowered to below Tg. After standing for a few minutes and removing the load, the shape of the sinus stent can be fixed, thereby obtaining a temporary shape memory sinus stent.
[0099] It has been found through experiments that the degradation rate of the shape memory sinus stent prepared in the above embodiments 1 to 2 is controllable, the hydrogel drug-loaded fiber membrane in the outermost layer can be degraded as early as within one month, the drug-loaded nanofiber membrane in the middle layer can be degraded within the second month, and the stent body in the innermost layer is degraded last, so that the sinus stent can fully play its role in all periods, and the sinus stent will gradually degrade in the human body, and the sinus stent will not be left in the sinus for a long time, reducing or eliminating the risk of potential complications, which is safer for the human body and avoids secondary surgery to remove the stent, which can effectively relieve pain and bring a better experience.
[0100] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A shape memory sinus stent, characterized in that: It comprises a stent body and a nano drug-loaded fiber membrane and a hydrogel drug-loaded fiber membrane sequentially coated on the surface of the stent body; wherein the stent body is composed of a top fixing point and a plurality of support bars uniformly arranged along the circumference of the top fixing point, one end of each support bar is connected to the top fixing point, and the other end is spread out in the direction away from the extension line of the top fixing point, so that the stent body has a bionic octopus structure; The stent body includes a temporary shape and an initial shape, both of which are bionic octopus structures, the size of the stent body in the initial shape is larger than the size of the stent body in the temporary shape, and the shape memory sinus stent can be transformed from the temporary shape to the initial shape when subjected to external stimulation.
2. The sinus stent according to claim 1, characterized in that: Each support bar is composed of a first arc close to the top fixing point and a second arc far from the top fixing point, the apex of the second arc is facing the extension line of the top fixing point, and the direction of the apex of the first arc is opposite to the direction of the apex of the second arc.
3. The sinus stent according to claim 2, characterized in that: The chord lengths of the first circular arcs in two adjacent support bars are different, and the chord lengths of the second circular arcs are also different.
4. The sinus stent according to claim 1, characterized in that: The support body also includes a plurality of top connecting members, and the top connecting members are located between two adjacent support bars and connected to the top fixing points.
5. The sinus stent according to claim 1 or 4, characterized in that: The support body further comprises a plurality of adsorbents, which are arranged on the support bar and are used to enhance the adsorption between the support body and the nasal cavity; Preferably, the adsorption component is composed of an annular adsorption disk and a cylindrical protrusion, and the cylindrical protrusion structure is located in the central area of the annular adsorption disk and is connected to the support bar.
6. The sinus stent according to claim 1, characterized in that: The degradation rates of the nano drug-loaded fiber membrane, hydrogel drug-loaded fiber membrane and the stent body are different; Preferably, the degradation rates of the hydrogel drug-loaded fiber membrane, the nano drug-loaded fiber membrane and the stent body decrease in sequence.
7. The sinus stent according to claim 1, characterized in that: The raw materials for preparing the stent body include shape memory racemic polylactic acid, biomedical polymer materials, and plasticizers; wherein the biomedical polymer materials are polylactic acid, glycolic acid-lactic acid copolymer, polycaprolactone, polyethylene glycol, polysuccinic acid co-succinate, polyglycolic acid, polytrimethylene carbonate, poly-p-dioxanone or polyvinyl alcohol, and the plasticizer is a vegetable oil-based plasticizer, a plant-based plasticizer, a bio-based plasticizer or a citrate plasticizer; Preferably, the raw material for preparing the stent body further includes a driving agent, and the driving agent is hollow copper sulfide particles.
8. The sinus stent according to claim 7, characterized in that: The raw materials for preparing the nano drug-loaded fiber membrane include shape memory racemic polylactic acid, biomedical polymer materials, additives and therapeutic drugs; wherein the additive is at least one of Centella asiatica, onion extract, chitosan, silk fibroin or chitosan, and the therapeutic drug is at least one of mometasone furoate, triamcinolone acetonide, budesonide, fluticasone propionate or beclomethasone propionate.
9. The sinus stent according to claim 7, characterized in that: The raw materials for preparing the hydrogel drug-loaded fiber membrane include natural polymer materials and therapeutic drugs; wherein the natural polymer material is at least one of chitosan, silk fibroin, sodium alginate, gelatin, hyaluronic acid, chitin or collagen.
10. The method for preparing a shape memory sinus stent according to any one of claims 1 to 9, characterized in that: The preparation method comprises the following steps: (1) constructing a three-dimensional structural model of the initial shape of the stent body according to the shape and size of the sinus structure; (2) mixing shape memory racemic polylactic acid, a biomedical polymer material and a driver to obtain a shape memory polymer, and performing 4D printing according to the three-dimensional structure model using the shape memory polymer as a printing line to obtain a stent body of an initial shape; (3) preparing a nano drug-loaded fiber membrane and a hydrogel drug-loaded fiber membrane respectively by an electrospinning method, and coating the nano drug-loaded fiber membrane and the hydrogel drug-loaded fiber membrane on the surface of the stent body in sequence to obtain a shape memory sinus stent of an initial shape; (4) The shape memory sinus stent of the initial shape is heated to above the glass transition temperature, a load is applied, and the shape memory sinus stent of the temporary shape is obtained after cooling and shaping.
Citation Information
Patent Citations
Device and methods for treating paranasal sinus conditions
CN101189016A
Expandable devices and methods therefor
CN102573981A
Paranasal sinus stent, supporting strip forming die and paranasal sinus stent manufacturing method
CN111494074A
Systems, devices, and method for treating a sinus condition
CN112089505A
Hydrogel porous silica gel airway stent and preparation method thereof
CN115591026A
Cited By
Intestinal retention hydrogel bionic drug release stent
CN120733234A
4D printing esophageal stent and preparation method thereof
CN120827647A
